FISHER & PAYKEL HEALTHCARE INTRODUCES NEW FLOW GENERATOR AND HUMIDIFICATION TECHNOLOGY FOR OSA TREATMENT

Auckland, New Zealand, 9 September 2004 - Fisher & Paykel Healthcare Corporation Limited (NZX:FPH, ASX:FPH) announced today that it has introduced a range of innovative flow generators which are intended for use in the treatment of obstructive sleep apnea (OSA).

The first two new products in the range are the HC600 series and the HC230 series. The company expects to introduce several additional devices based on the new platform over the next two years.

The HC600 incorporates ThermoSmart™ heated breathing tube technology which provides optimal levels of humidity independent of external conditions. The company believes that the benefits of ThermoSmart™ will include reduced symptoms due to airway drying, improved patient comfort and more effective continuous positive airway pressure (CPAP) therapy.

The HC230 integrated flow generator offers a greater pressure range, altitude adjustment and enhanced user ergonomics. The HC230 series also incorporates Fisher & Paykel Healthcare’s patented Ambient Tracking® PLUS auto-adjusting humidification technology.

“We believe that these new products will offer significant benefits for OSA treatment. In the HC600 we have applied our world leading intensive care humidification technology to OSA therapy, providing increased humidity which can enhance treatment for CPAP users.” said Michael Daniell, Fisher & Paykel Healthcare’s Managing Director and CEO.

Both new flow generators have been introduced in New Zealand, Australia and Europe. The HC230 series has received FDA clearance and will be introduced in the United States in October. The HC600 series will be introduced in the US once FDA clearance has been received.

**HC600 series** with ThermoSmart™ heated breathing tube technology

**HC230 series** with Ambient Tracking™ PLUS auto-adjusting humidification technology
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of heated humidification products and systems for use in respiratory care and the treatment of obstructive sleep apnea. It also offers an innovative range of patient warming devices and neonatal care products. The company’s products are sold in over 90 countries worldwide.

Further information can be obtained by contacting Michael Daniell MD/CEO on +64 9 574 0161 or Tony Barclay CFO on +64 9 574 0119 at Fisher & Paykel Healthcare Corporation Limited or by visiting the company’s website at www.fphcare.com

Ends//